Caladrius Biosciences Inc (CLBS)

1.81 +0.06  +3.43% NASDAQ Jul 6, 16:59 Delayed 2m USD
View Full Chart
Price Chart
View All Events

Events

Date Type Description
03/13/2020 16:30 EDT Misc Caladrius Biosciences Inc Fourth Quarter Earnings Conference Call in 2019
03/13/2020 Earnings Caladrius Biosciences Inc Fourth Quarter Earnings in 2019 Release
11/06/2019 16:30 EST Misc Caladrius Biosciences Inc Third Quarter Earnings Conference Call for 2019
11/06/2019 Earnings Caladrius Biosciences Inc Third Quarter Earnings in 2019 Release
08/08/2019 16:30 EDT Misc Caladrius Biosciences Inc Second Quarter Earnings Conference Call in 2019
08/08/2019 Earnings Caladrius Biosciences Inc Second Quarter Earnings in 2019 Release
View All Performance Charts

Total Returns Comparison

Ratings & Reports

Advertisement
Edit

Profile

  • URL: http://www.caladrius.com
  • Investor Relations URL: http://www.caladrius.com/investors/overview/
  • HQ State/Province: New Jersey
  • Sector: Healthcare
  • Industry: Biotechnology
  • Equity Style: Small Cap/Value
  • Next Earnings Release: N/A
  • Last Earnings Release: Mar. 13, 2020
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: Oct. 28, 2013
  • Description: Caladrius Biosciences Inc is a clinical-stage biopharmaceutical company developing cellular therapies designed to reverse, not manage, disease. The company's product candidates include: CLBS119, for the repair of lung damage found in patients with severe COVID-19 infection who experienced respiratory failure, clinical trial to be initiated in 3Q2020 (USA); CLBS12, recipient of a SAKIGAKE (Japan) and ATMP (Europe) designations, eligible for early conditional approval for the treatment of critical limb ischemia based on an ongoing clinical trial (Japan); CLBS16, subject of the completed proof-of-concept ESCaPE-CMD clinical and planned Phase 2B (U.S.A.); and CLBS14, a Phase 3 ready clinical program in no option refractory disabling angina and recipient of a RMAT designation (USA).

Comparables

Edit
Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.